SEC filing summary
Important identity mismatch: The request identifies Neurogene Inc., but the supplied Form 10-Q is for Aquinox Pharmaceuticals, Inc. This summary describes the supplied filing, not a Neurogene filing.
Business context and reporting period
Aquinox is a clinical-stage pharmaceutical company focused on SHIP1-targeting therapeutics. Its lead candidate, AQX-1125, was being developed for interstitial cystitis/bladder pain syndrome (IC/BPS). This unaudited 10-Q covers the quarter and nine months ended September 30, 2016; financial statements are in U.S. dollars. The company reported no revenue.
Financial performance and liquidity
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $6.1 million | $3.7 million | $20.3 million | $11.9 million |
| General and administrative | $2.1 million | $1.2 million | $5.9 million | $3.9 million |
| Total operating expenses | $8.3 million | $4.9 million | $26.2 million | $15.7 million |
| Net loss | $8.1 million | $5.0 million | $25.8 million | $16.2 million |
| Basic and diluted loss per share | $0.46 | $0.43 | $1.48 | $1.46 |
| Cash used in operations | Not provided for quarter | Not provided for quarter | $21.2 million | $16.3 million |
Margins: Not meaningful because the company had no revenue. Liquidity: At September 30, 2016, cash and cash equivalents were $86.2 million, short- and long-term investments totaled $76.4 million, and working capital was $138.0 million. Total cash, cash equivalents and investments were $162.6 million. Total liabilities were $8.7 million, including $8.6 million of current liabilities; the filing shows no outstanding debt balance. Management said existing resources were expected to fund operations for at least 12 months, while anticipating substantial future financing needs.
Financing cash flow included $75.4 million of gross proceeds from a September 2016 public offering, before $4.5 million in underwriting discounts and commissions and other offering expenses. The offering increased shares outstanding to 23.4 million at quarter-end from 17.2 million at December 31, 2015.
Material changes versus comparable periods
- Nine-month net loss rose to $25.8 million from $16.2 million; operating expenses increased to $26.2 million from $15.7 million.
- R&D spending increased, primarily with initiation of the Leadership 301 Phase 3 IC/BPS trial. Nine-month R&D also included a $2.3 million accrued milestone payment to Biolipox.
- G&A increased, which the company attributed mainly to higher personnel costs and opening a San Bruno, California office.
- Cash used in operations rose to $21.2 million from $16.3 million. The company’s cash balance increased from $39.5 million at year-end 2015, largely reflecting the September offering.
- Interest income increased as cash and investment balances grew. The prior-year nine-month period included $0.4 million of foreign-exchange losses, versus immaterial foreign-exchange losses in 2016.
Outlook, commentary, risks and unusual items
- Leadership 301 began in Q3 2016: a randomized, double-blind, placebo-controlled Phase 3 study of two potential AQX-1125 doses in IC/BPS patients, with 12 weeks of dosing and an extension of up to 40 weeks. The company said the design of a second planned Phase 3 trial would be informed by Leadership 301 results after patients completed 12 weeks.
- The filing describes mixed prior evidence: Leadership 201 showed a positive trend and statistically significant secondary-endpoint changes, but did not achieve statistical significance on its primary endpoint. The company also reported that Phase 2 trials in COPD and atopic dermatitis failed to demonstrate efficacy and said it was not planning further development for those indications.
- Management expected higher R&D costs as clinical development continued. The company had no approved products, no revenue, and an accumulated deficit of $137.0 million; profitability was not expected in the foreseeable future.
- Key risks include clinical-trial efficacy, safety and enrollment; the unvalidated SHIP1 target; regulatory uncertainty; reliance on contract research organizations and manufacturers; intellectual-property challenges; and the possibility that additional financing may be unavailable or dilutive. The filing notes gastrointestinal side effects in trials and adverse findings in animal toxicity studies.
- A $2.3 million Biolipox milestone was accrued; up to an additional CAD $1.5 million could become payable upon first commercial sale in the United States, Europe or Japan. The filing reported no material changes to previously disclosed contractual commitments and no off-balance-sheet arrangements.
- The company held $148.9 million in U.S. government securities and estimated that a hypothetical 100-basis-point interest-rate increase would reduce portfolio fair value by $0.6 million. It did not hedge foreign-currency exposure.
- The Baker entities were reported to beneficially own approximately 45.1% of common stock as of September 19, 2016. A registration-rights agreement could permit them to demand resale registration after December 19, 2016. The filing also disclosed remaining capacity under registered securities offerings.
Most important facts for investors to verify
- Confirm the issuer: the supplied document is Aquinox Pharmaceuticals’ 2016 Q3 10-Q, not a Neurogene Inc. filing.
- Check Leadership 301’s enrollment, timing, dose selection and results, and how its findings affect the planned second Phase 3 study.
- Reconcile the mixed description of Leadership 201 across the filing, particularly its nonsignificant primary endpoint and favorable secondary-endpoint findings.
- Assess cash runway against the $21.2 million nine-month operating cash use, expected trial-cost increases and management’s stated need for future financing.
- Review dilution and potential share supply from the 2016 offering, outstanding equity awards, registration rights and remaining securities-offering capacity.